CN Patent

CN117510447B — 一种达格列净-吡格列酮共无定形物及其制备方法和应用

Assigned to Hebei Medical University · Expires 2025-08-12 · 1y expired

What this patent protects

本发明涉及一种达格列净‑吡格列酮共无定形物及其制备方法和应用，所述达格列净‑吡格列酮共无定形物中，达格列净和吡格列酮的摩尔比为1:2~2:1，其X‑射线粉末衍射图谱没有尖锐的衍射峰，表明了共无定形态的形成。本发明通过利用溶剂辅助研磨法和旋转蒸发法获得共无定形，经过试验验证，该无定形具有良好的溶解度、溶出度、生物利用度，经体内和体外降糖活性试验验证，明显优于单独应用达格列净或吡格列酮的活性，由此可见本申请共无定形超分子体系中达格列净‑吡格列酮具有协同降糖作用。

USPTO Abstract

本发明涉及一种达格列净‑吡格列酮共无定形物及其制备方法和应用，所述达格列净‑吡格列酮共无定形物中，达格列净和吡格列酮的摩尔比为1:2~2:1，其X‑射线粉末衍射图谱没有尖锐的衍射峰，表明了共无定形态的形成。本发明通过利用溶剂辅助研磨法和旋转蒸发法获得共无定形，经过试验验证，该无定形具有良好的溶解度、溶出度、生物利用度，经体内和体外降糖活性试验验证，明显优于单独应用达格列净或吡格列酮的活性，由此可见本申请共无定形超分子体系中达格列净‑吡格列酮具有协同降糖作用。

Drugs covered by this patent

Patent Metadata

Patent number
CN117510447B
Jurisdiction
CN
Classification
—
Expires
2025-08-12
Drug substance claim
No
Drug product claim
No
Assignee
Hebei Medical University
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.